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P R E V I E W S
Persistent proliferation and enhanced
cell survival are hallmarks of aggressive
tumor cells. Two key proteins that sup-
press abnormal cell proliferation are the
RB and p53 tumor suppressors. RB acts
as a brake to block cell cycle progression
through its ability to repress E2F, a tran-
scription factor that activates genes
essential for the S phase of the cell cycle
(for review, see Sherr, 2004). p53 also
blocks cell proliferation in part by induc-
ing p21CIP1, a protein that binds and
inhibits the cyclin/CDK complexes, which
are required for progression through the
cell cycle. Additionally, p53 induces cell
death by activating the expression of
genes involved in apoptosis (for review,
see Vogelstein et al., 2000). Therefore,
not surprisingly, most cancer cells have
inactivated both of these factors either
directly or indirectly to sever their signal-
ing pathways.
Recently, Fujita and colleagues
(Higashitsuji et al., 2000) identified
gankyrin as a gene that was consistently
overexpressed in human liver cancers.
Gankyrin is highly conserved throughout
evolution (?40% identity to yeast Nas6P)
(Hori et al. 1998) and is localized on
human chromosome Xq22.3 in a region
where DNA gains are frequently detected
in kidney and colon carcinomas. Whether
gankyrin expression is deregulated in
cancers other than liver tumors is not yet
known. Gankyrin contains two special
domains consisting of ankyrin repeats
and the RB-recognition motif LxCxE
(178LACDE182), and derives its name from
these features. “Gann” is the Japanese
word for cancer, and ankyrin is the func-
tional domain involved in protein-protein
interactions.
Gankyrin was initially purified and
characterized by Tanaka and coworkers
(Hori et al., 1998) as the p28 component
of the regulatory subunit of the 26S pro-
teasome, which is an ATP-dependent
protease responsible for the degradation
of proteins.The observation that gankyrin
binds RB, but not p107 or p130 (RB relat-
ed proteins), in vitro and in vivo when
ectopically expressed provided an initial
glimpse into the role of gankyrin in
tumorigenesis (Higashitsuji et al., 2000).
Consistent with these findings, enforced
expression of gankyrin in immortalized
mouse fibroblasts and human tumor cells
conferred growth in soft agar, and this
transformation phenotype was depen-
dent on the ability of gankyrin to bind RB
(e.g., the LxCxE point mutant E182A is
inactive). Interestingly, a splice variant of
gankyrin is produced that lacks the
LACDE motif, which should render it
inactive in targeting RB directly. However,
the physiologic role of this variant and
how gankyrin gene expression is regulat-
ed in general has not yet been explored.
Gankyrin facilitates the phosphorylation
and degradation of RB (Figure 1), sug-
gesting that increased expression of
gankyrin promotes tumorigenicity by tar-
geting RB to the proteasome. Yet
gankyrin disrupts RB function by other
means as well. Gankyrin also binds
cyclin-dependent kinase 4 (CDK4) result-
ing in a gankyrin-CDK4-Cyclin D ternary
complex (Li and Tsai, 2002). In so doing,
gankyrin competes with INK4A, an
inhibitor of cyclin kinases, for binding to
CDK4. Based upon these findings,
gankyrin appears to indirectly activate
CDK4, resulting in the hyperphosphory-
lation of RB and concomitant deregula-
tion of E2F1-mediated transcription and
cell cycle progression (Figure 1). Taken
together, these studies suggest that
gankyrin deactivates the RB tumor sup-
pressor pathway at multiple levels,
including by direct binding to RB and by
ensuring its inactivation through the
maintenance of CDK4 kinase activity.
In the present study in Cancer Cell
by Fujita and colleagues (Higashitsuji et
al., 2005), gankyrin is now shown to bind
to MDM2, an E3 ubiquitin ligase that
negatively regulates p53. Compelling
data are provided showing that this inter-
action occurs naturally between endoge-
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The RB and p53 tumor suppressors lie at the heart of cancer biology, and inactivation of both pathways is seemingly
essential for tumor development. Previous studies identified gankyrin as a component of the 26S proteasome that is con-
sistently overexpressed in liver cancer and promotes cell transformation by binding RB. In the current issue of Cancer Cell,
Fujita and colleagues (Higashitsuji et al., 2005) show that gankyrin also binds MDM2 and facilitates its destruction of p53.
These important findings implicate gankyrin as a dual-purpose negative regulator of RB and p53, thereby identifying
gankyrin as a rational cancer therapeutic target.
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nous gankyrin and MDM2 and that
gankyrin enhances the ability of MDM2
to ubiquitinate p53. Consequently,
gankyrin recruits the MDM2 and p53
complex to the proteasome and fosters
the turnover of p53 in an MDM2-depen-
dent manner. Moreover, downregulation
of gankyrin expression by RNAi
increased p53 protein levels and activity,
and promoted apoptosis. These findings
indicate that gankyrin functions as a neg-
ative regulator of p53 by modulating
MDM2 activity. Most importantly, this
study provides a plausible mechanism
for targeting p53 to the proteasome by
MDM2 through its association with
gankyrin, an integral component of the
26S proteasome. This study thus
expands the role of gankyrin in tumorige-
nesis by disruption of both the RB and
p53 tumor suppressor pathways.
Emerging evidence demonstrates
that discrete changes in MDM2 expres-
sion can play a critical role in maintaining
normal p53 function and cell physiology.
Diminished p53 activity allows increased
proliferation and inhibition of apoptosis,
providing advantageous signals for tumor
cell survival. Too much p53, on the other
hand, stifles cell proliferation and leads 
to apoptosis. Mouse models support
these observations. Mice overexpressing
Mdm2 are tumor-prone, while those lack-
ing Mdm2 die early in embryogenesis
due to increased p53 activity (Lozano
and Zambetti, 2005). A hypomorphic
allele of Mdm2 further exemplifies the
importance of Mdm2 levels in regulating
cell proliferation and survival. Mice that
express about one-third of the normal
Mdm2 levels are small and anemic, with
fewer hematopoetic cells (Mendrysa et
al., 2003). This phenotype disappears in
the absence of p53. In humans, MDM2
expression is modulated by a single
nucleotide polymorphism (SNP309) with-
in the promoter region
(Bond et al., 2004). This
polymorphism results in
increased MDM2 levels
and thus decreased p53
activity. Individuals who
have inherited a defective p53 allele and
the SNP309 develop cancer with signifi-
cantly shorter latencies as compared to
mutant p53 carriers without this polymor-
phism. Thus, any modulation of MDM2
activity is likely to have consequences on
cell survival and tumorigenesis.
As such, the observation presented
in the current study, that gankyrin facili-
tates MDM2 E3 ligase activity, has
important implications in tumorigenesis.
Decreased activity of gankyrin should
ultimately lead to increased p53 levels
and decreased risk of cancer. By con-
trast, an increase in the activity of
gankyrin should facilitate MDM2 inacti-
vation of p53 function and lead to a
tumor-prone phenotype (Figure 1).
Additionally, the ultimate effect on
tumorigenesis may be amplified, since
gankyrin can also inhibit the activity of
the RB tumor suppressor. In this sense,
gankyrin imitates the function of trans-
forming proteins such as the Large T
antigen from SV40 virus, which binds
and inactivates both p53 and RB (Pipas
and Levine, 2001).
While these biochemical data provide
novel insight into the mechanism by which
gankyrin may promote tumorigenesis,
many questions remain to be addressed.
The recognition that gankyrin binds both
Rb and p53 suggests that it may be over-
expressed in many tumor types. To date,
however, only hepatocellular carcinomas
have been examined. Additionally, how
does such a small protein (gankyrin is 25
KDa in size) bind RB, Cdk4, MDM2, and
the proteasome? Does it do so collective-
ly or independently? Other components of
the proteasome may potentially aid in
attracting these proteins and shuttling
them down the degradation pathway. The
intriguing findings presented in the cur-
rent study (Higashitsuji et al., 2005) impli-
cate gankyrin as a contributory factor in
tumor development and highlight this fac-
tor as a potentially important therapeutic
target. Challenging the functional role of
gankyrin in regulating the p53 and RB
pathways in a knockout mouse model
should yield invaluable insight into its role
as a potential modifier of tumorigenesis.
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Figure 1. The gankyrin regulatory circuit
Gankyrin interacts with MDM2 and facilitates the ubiquitination and targeting of
p53 to the proteasome for degradation. Gankyrin also binds RB to promote RB
phosphorylation and degradation. In parallel, gankyrin binds CDK4, which pre-
cludes INK4A binding to the cyclin kinase, resulting in enhanced RB phosphory-
lation and stimulation of E2F transcriptional activity, thus causing cell cycle
progression. Gankyrin therefore functions as a dual-negative regulator of the
two most prominent tumor suppressor pathways, RB and p53.
